ChronoFOLFOX Plus Avastin for Patients With Metastatic Colorectal Cancer

Southwestern Regional Medical Center

Status and phase: Terminated; Phase 2

Conditions: Colorectal Neoplasms

Treatments: Drug: 5-Fluorouracil, leucovorin, oxaliplatin, avastin

Study type: Interventional

Funder types: Other

Identifiers

NCT00385021

CTCT 06-06

Details and patient eligibility

About

To determine efficacy in the delivery of chronomodulated chemotherapy.

Full description

The purpose of this study is to determine if treatment with 5-Fluorouracil, leucovorin, oxaliplatin, and Avastin will cause colorectal tumor cells to shrink or disappear. The study will also determine the safety of these drugs when given together and the quality of life of the patients who are enrolled in the study.

It is thought that these drugs will be better tolerated if they are chronomodulated, i.e., if they are given at certain times of day rather than as a continuous infusion.

Enrollment: 20 estimated patients

Sex: All

Ages: 18 to 86 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Histological proof of adenocarcinoma in primary colon or rectum tumor.
• Evidence of metastatic colorectal cancer or loco-regional recurrence or unresectable disease.
• Ages 18 to 86 years.
• Presence of at least one bi-dimensionally measurable disease with at least one diameter > or = 2 cm.
• WHO/ECOG performance status < 3 (0, 1, or 2)
• Prior treatment with oxaliplatin, 5-FU, or leucovorin permitted.
• Signed informed consent

Exclusion criteria

• Peripheral sensory neuropathy > or = grade 3.
• Serum bilirubin (total) > 3 X ULN.
• Symptomatic or uncontrolled brain metastasis.
• Metastases limited to bone, pleural effusion, or ascites.
• Uncontrolled overt cardiac disease.
• Uncontrolled hypercalcemia.
• Uncontrolled infections.
• Uncontrolled hypertension (>180/110)
• History of GI perforation.
• History of arterial thromboembolic events.
• History of congestive heart failure.
• Patients taking warfarin (Coumadin).
• Patients who are pregnant.

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)